Catalent Inc (CTLT) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Catalent Inc (NASDAQ:CTLT) from a hold rating to a buy rating in a report released on Thursday morning. The firm currently has $31.00 price target on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other analysts have also recently issued research reports about the stock. TheStreet raised shares of Catalent from a d+ rating to a c rating in a research note on Monday, February 6th. Jefferies Group LLC boosted their target price on shares of Catalent from $29.00 to $32.00 and gave the stock a hold rating in a research note on Monday, February 27th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Catalent currently has an average rating of Buy and an average price target of $29.50.
Catalent (NASDAQ:CTLT) traded down 1.13% during midday trading on Thursday, hitting $27.97. The stock had a trading volume of 200,075 shares. The company’s 50 day moving average is $28.38 and its 200 day moving average is $26.53. The company has a market cap of $3.49 billion and a price-to-earnings ratio of 38.90. Catalent has a 1-year low of $20.94 and a 1-year high of $30.28.
Catalent (NASDAQ:CTLT) last posted its earnings results on Monday, February 6th. The company reported $0.27 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.27. The company had revenue of $483.70 million for the quarter, compared to the consensus estimate of $474.07 million. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 EPS. On average, equities analysts anticipate that Catalent will post $1.39 earnings per share for the current fiscal year.
In other Catalent news, insider John R. Chiminski sold 73,819 shares of the company’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $28.62, for a total transaction of $2,112,699.78. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the business’s stock in a transaction on Wednesday, February 15th. The shares were purchased at an average cost of $29.27 per share, for a total transaction of $292,700.00. The disclosure for this purchase can be found here.
A number of hedge funds have recently modified their holdings of the stock. Louisiana State Employees Retirement System boosted its stake in shares of Catalent by 2.3% in the first quarter. Louisiana State Employees Retirement System now owns 31,500 shares of the company’s stock worth $892,000 after buying an additional 700 shares during the period. CWM LLC purchased a new stake in shares of Catalent during the first quarter worth approximately $2,508,000. Fox Run Management L.L.C. purchased a new stake in shares of Catalent during the first quarter worth approximately $346,000. Parametrica Management Ltd purchased a new stake in shares of Catalent during the first quarter worth approximately $308,000. Finally, Capstone Asset Management Co. boosted its stake in shares of Catalent by 3.4% in the first quarter. Capstone Asset Management Co. now owns 9,900 shares of the company’s stock worth $280,000 after buying an additional 330 shares during the period.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.